Investors have become more attracted to longevity stocks with the world’s population aging quickly. These companies aim to delay, slow down or reverse aging through targeting various age-related diseases.
One option to consider is AAA-rated Medtronic (US:MDT), a medical devices manufacturer serving an aging population. Another NASDAQ-listed option would be Unity Biotechnology.
Biotechnology
Searching for immortality may sound like the obsession of superhero-movie villains, but biotech companies and billionaires with plenty of cash are investing in research that may reverse aging processes. While some might view such products as “immortality pills”, their products might extend lifespans by treating age-related ailments more effectively than ever before.
However, biotech firms still face significant obstacles in becoming competitive against bigger drugmakers when it comes to profitability and valuations. Therefore, investors in biotech should remain patient as the overall industry struggles to catch up in this regard.
As stocks focusing on longevity trends remain early-stage companies, many are seeking the key to human longevity by targeting neurodegenerative diseases that disproportionately impact older individuals – for instance Denali Therapeutics’ (DNLI) experimental Alzheimer’s drug could lengthen life at either extreme of current aging spectrum.
Clinical-stage drug candidates being developed by this company range in stage from early development to clinical testing and are intended to treat neurodegenerative conditions, including amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease. ATL-602 specifically targets Alzheimer’s patients characterized by tau protein accumulation.
Furthermore, ATL-602’s dual-purpose mechanism aims to combat the aging effects on cardiovascular system by reducing vascular inflammation and improving blood flow to help prevent progression of disease.
Other biotechnology firms are targeting age-related chronic diseases that drive most healthcare spending. Examples of such firms are Altos Labs (ARCH), which has raised $3 billion, and NewLimit, funded by cryptocurrency billionaire Brian Armstrong.
Cambrian Biopharma (CMB), with an aim of lengthening mouse lifespan through genetic modification, uses an RNA-based approach which may also extend human lifespan. They have partnered with University of California San Francisco in developing their technologies.
Artificial Intelligence
Silicon Valley billionaires have long dreamed of creating the Fountain of Youth; Google’s Calico, Oracle co-founder Larry Ellison’s Longevity Fund and AgeX are putting money toward technologies which may one day slow the aging process, extend lifespans and promote health preservation.
New Limit, another stock designed to reverse aging, utilizes cutting-edge single cell genomics and epigenetics tools to reprogram cells in the body to act younger. They have already demonstrated this success with mice; now their goal is to decrease functional performance differences between actual young cells and reprogrammed old ones.
Longevity Stocks
Anti-Aging industry: an investment opportunity? The anti-Aging industry is a multibillion-dollar space comprised of cosmetic companies marketing to older consumers and tech firms using artificial intelligence for long-term care at home. Investors should note that longevity stocks also include biotechnology companies working to address specific ailments related to ageing.
These stocks can be especially captivating investments as they focus on treating late-stage illnesses like cancer, Alzheimer’s and dementias. While these treatments might not completely reverse aging processes, they may be able to slow their progression while providing patients with improved quality of life.
As the industry develops, some of these companies may provide real value. Therefore, you should conduct detailed research on each one to make sure they possess the required team and assets. Some are already making strides forward; Biogen (NASDAQ:BIIB) recently developed a drug which helps slow the degeneration of nerve cells in the brain which may extend life significantly; it received FDA approval for this treatment, leading to a surge in its share price.
Qualcomm and Nvidia could also make excellent longevity stocks to include in your portfolio, both of which design and produce computer chips for use in healthcare settings; Alphabet also has a subsidiary dedicated to extending human lifespan, offering indirect exposure to this trend across various sectors.
Human Longevity (NASDAQ:HLI) offers another viable investment option for longevity-minded investors. This ETF seeks to identify and capitalize on technologies and biological breakthroughs that extend lifespan, health, and high performance; its portfolio features several promising companies developing drugs specifically targeted towards treating conditions common among senior populations.
This ETF could offer an effective means of capitalizing on the growth in longevity economics and aging demographic trends, while its low correlation to other asset class risks make it an excellent way to diversify your investment portfolio.